Masayendisiti kubva kumakambani maviri aya akaongorora kutevedzana kweiyo SARS-CoV-2 Omicron musiyano, yakasarudzwa hutachiona sequences, uye akagadzirwa plasmid clones. Isu tinotarisira iyo mitsva yeOmicron SARS-CoV-2 yekudzivirira inogona kukwidziridzwa mukuedzwa kwekiriniki mukati memazuva asingasviki zana.
"Isu tinotenda zvakakosha kugadzira mishonga mitsva yekudzivirira nekukurumidza uye nemazvo kurwisa iyo itsva Omicron COVID-19 musiyano. Tichashanda pamwe chete nemasangano anodzora uye kutsvaga zvidzidzo zvekiriniki zvakakodzera uye mvumo yekuunza mushonga uyu kumusika nekukurumidza. " akadaro Brad Sorenson, CEO weProvidence Therapeutics.
"Tinotarisira kukurumidza kugadzira iyi itsva yekudzivirira yeOmicron neProvidence, uye kuunza pundutso yejekiseni iri munzvimbo dziya dzine mukana wakaderera wekurapa kwazvino mRNA." akadaro Kerry Blanchard, MD, PhD, Chief Executive Officer weEverest Medicines.
ZVOKUBVA MUNYAYA INO:
- “We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular.
- “We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
- We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.
